FOCL
EDAP TMS S.A.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
4.10
▼ 0.14 (3.30%)
MARKET · —
Price
Open
4.24
Prev close
4.24
Day high
4.24
Day low
4.08
Volume
236.35K
Market cap
$154.99M
P/E (TTM)
—
52W range
1.30 – 6.40
Trailing performance
Returnvs SPY
1W
-13.24%
-11.9%
1M
-32.18%
-35.9%
3M
-4.62%
-7.7%
6M
-12.31%
-23.4%
YTD
+25.53%
+13.2%
1Y
+199.28%
+179.3%
3Y
-49.82%
-124.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$154.99M
Enterprise value$209.92M
Revenue (TTM)$79.31M
Gross profit$35.28M
EBITDA$-23.67M
Net income$-39.12M
EPS (TTM)$-1.04
Free cash flow$-12.74M
Total cash$21.54M
Total debt$41.68M
Book value / share$-0.09
Shares outstanding37.53M
Float36.25M
Short % of float0.90%
Dividend yield—
Beta (5Y)-0.03
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.50
PEG ratio—
Price / sales—
Price / book—
EV / revenue2.65
EV / EBITDA-8.87
Gross margin44.48%
Operating margin-60.83%
Profit margin-49.13%
Return on equity-265.67%
Return on assets-22.11%
Debt / equity—
Current ratio1.60
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $72.32M | $69.15M | $65.41M | $60.10M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$29.99M | -$20.51M | -$22.93M | -$3.20M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$29.99M | -$20.51M | -$22.93M | -$3.20M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.20 | -0.24 | -19.1% |
| Mar 2026 | -0.22 | -0.24 | -11.6% |
| Dec 2025 | -0.16 | -0.25 | -62.4% |
| Sep 2025 | -0.26 | -0.15 | +42.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.26 | 1 | $11.80M | -26.3% |
| Next quarter | -0.27 | 1 | $15.40M | -29.8% |
| Current year | -1.04 | 1 | $52.05M | -28.0% |
| Next year | -0.64 | 4 | $72.14M | +38.6% |
Analyst targets & ownership
Mean target$8.60
High target$15.00
Low target$3.00
Implied upside109.76%
Analyst count5
ConsensusBUY
Strong buy / Buy0 / 3
Hold2
Sell / Strong sell0 / 0
Held by insiders5.11%
Held by institutions31.32%
Institutions holding38
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.35M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | WILLSEY LANCE Director |
BUY | 50.00K | $237.50K | Direct |
| Aug 14, 26 | LEVINE JOSHUA H Director |
BUY | 10.00K | $47.50K | Direct |
| Aug 14, 26 | ANNEN STEVEN Officer |
BUY | 5.00K | $23.75K | Direct |
| Aug 14, 26 | RHODES RYAN Chief Executive Officer |
BUY | 21.00K | $99.75K | Direct |
| Aug 14, 26 | HORN DAVID R. Director |
BUY | 10.00K | $47.50K | Direct |
| Aug 14, 26 | SHAH SANKET General Counsel |
BUY | 5.00K | $23.75K | Direct |
| Aug 14, 26 | SCHULZ FRAN Director |
BUY | 10.00K | $47.50K | Direct |
| Aug 14, 26 | MOBECK KENNETH S. Chief Financial Officer |
BUY | 5.00K | $23.75K | Direct |
| May 12, 26 | ANNEN STEVEN Officer |
STOCK | 90.00K | $0 | Direct |
| May 12, 26 | RHODES RYAN Chief Executive Officer |
STOCK | 304.50K | $0 | Direct |
| May 12, 26 | SHAH SANKET General Counsel |
STOCK | 67.50K | $0 | Direct |
| May 12, 26 | MOBECK KENNETH S. Chief Financial Officer |
STOCK | 120.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANNEN STEVEN |
Officer | 136.49K | Purchase |
HORN DAVID R. |
Director | 10.00K | Purchase |
LEVINE JOSHUA H |
Director | 45.00K | Purchase |
MOBECK KENNETH S. |
Chief Financial Officer | 181.61K | Purchase |
RHODES RYAN |
Chief Executive Officer | 626.65K | Purchase |
SCHULZ FRAN |
Director | 15.10K | Purchase |
SHAH SANKET |
General Counsel | 72.50K | Purchase |
WILLSEY LANCE |
Director | 1.29M | Purchase |
Moving averages & technicals
SMA 10
4.76
-13.83% from price
SMA 20
5.45
-24.23% from price
SMA 50
5.34
-22.64% from price
SMA 100
4.60
-10.87% from price
SMA 200
4.04
+2.32% from price
EMA 12
4.81
-14.68% from price
EMA 26
5.17
-20.68% from price
EMA 50
5.15
-20.39% from price
RSI (14)
27.2
Oversold
MACD (12,26,9)
-0.36
Hist -0.21
ATR (14)
0.39
9.44% of price
Realised vol 30D
80.4%
Annualised
Bollinger upper
7.14
20, 2σ
Bollinger lower
3.76
20, 2σ
50 / 200 cross
Golden
5.34 vs 4.04
Trend bias
Above 200
+2.32%
Risk profile
Beta vs SPY
0.62
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
80.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-35.4%
Peak to trough
Max drawdown 5Y
-90.0%
Peak to trough
ATR 14
0.39
9.44% of price
Beta (reported)
-0.03
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.08
Positioning, not flow
Max pain
2.50
-39.5% from spot
ATM implied vol
93.4%
Nearest strike to spot
Skew (10% OTM)
+30.1%
Puts bid over calls
Call volume
144
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
7.50
211 contracts
Heaviest put OI
2.50
29 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading
MT Newswires · 1d ago
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires · 2d ago
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
MT Newswires · 5d ago
Edap TMS SA (FOCL) (Q2 2026) Earnings Call Highlights: HIFU Revenue Surges 39% as Company ...
GuruFocus.com · 9d ago
FocalTherics Q2 Earnings Call Highlights
MarketBeat · 9d ago
FocalTherics™ Reports Second Quarter 2026 Financial Results
GlobeNewswire · 9d ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
MT Newswires · 10d ago
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
GlobeNewswire · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.